VRTX · Insider Trading
Vertex Pharmaceuticals Inc
Every open-market purchase and sale reported by VRTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Jasper van Grunsven | EVP, CP and NPPO | A | +8,682 | — |
| 2026-09-01 | Kristen Ambrose | SVP & Chief Accounting Officer | A | +5,000 | — |
| 2026-08-31 | Bruce I Sachs | Director | G | −6,000 | — |
| 2026-07-23 | Amit Sachdev | EVP Chief Patient & Ext Af Off | A | +8,251 | — |
| 2026-07-23 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | A | +8,251 | — |
| 2026-07-17 | Alan M Garber | Director | A | +31 deriv. | — |
| 2026-07-17 | Bruce I Sachs | Director | A | +99 deriv. | — |
| 2026-07-07 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | −1,541 | −$799.78K |
| 2026-07-07 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sell | −1,500 | −$787.49K |
| 2026-07-06 | Joy Liu | EVP and Chief Legal Officer | Sell | −828 | −$416.24K |
| 2026-06-23 | Carmen Bozic | EVP and CMO | Sell | −1,020 | −$471.41K |
| 2026-06-17 | Carmen Bozic | EVP and CMO | Sell | −4,062 | −$1.83M |
| 2026-06-09 | Carmen Bozic | EVP and CMO | Sell | −1,745 | −$785.25K |
| 2026-06-03 | Joy Liu | EVP and Chief Legal Officer | Sell | −828 | −$364.25K |
| 2026-06-02 | Carmen Bozic | EVP and CMO | Sell | −1,974 | −$888.30K |
| 2026-05-19 | Carmen Bozic | EVP and CMO | Sell | −1,354 | −$613.97K |
| 2026-05-19 | Mark E. Bunnage | EVP, Chief Scientific Officer | Sell | −33 | −$14.96K |
| 2026-05-14 | Carmen Bozic | EVP and CMO | Sell | −6,988 | −$3.14M |
| 2026-05-05 | Sangeeta N. Bhatia | Director | MIXED | +625 | −$134.75K |
| 2026-05-05 | Lloyd Carney | Director | A | +2,866 deriv. | — |
| 2026-05-05 | Alan M Garber | Director | A | +472 | — |
| 2026-05-05 | Michel Lagarde | Director | A | +2,866 deriv. | — |
| 2026-05-05 | Joy Liu | EVP and Chief Legal Officer | Sell | −1,104 | −$469.22K |
| 2026-05-05 | Diana McKenzie | Director | MIXED | +147 | — |
| 2026-05-05 | Bruce I Sachs | Director | A | +2,866 deriv. | — |
| 2026-05-05 | Jennifer Schneider | Director | MIXED | −324 | — |
| 2026-05-05 | Nancy Thornberry | Director | MIXED | +74 | — |
| 2026-05-05 | Suketu Upadhyay | Director | D | −796 | — |
| 2026-04-17 | Alan M Garber | Director | A | +33 deriv. | — |
| 2026-04-17 | Bruce I Sachs | Director | A | +107 deriv. | — |
| 2026-04-17 | Suketu Upadhyay | Director | A | +80 deriv. | — |
| 2026-04-03 | Joy Liu | EVP and Chief Legal Officer | Sell | −978 | −$439.29K |
| 2026-03-31 | Carmen Bozic | EVP and CMO | Sell | −2,329 | −$1.05M |
| 2026-03-17 | Carmen Bozic | EVP and CMO | Sell | −2,329 | −$1.12M |
| 2026-03-13 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | −2,633 | −$1.31M |
| 2026-03-06 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | −2,437 | −$1.16M |
| 2026-03-04 | Joy Liu | EVP and Chief Legal Officer | Sell | −892 | −$442.40K |
| 2026-03-03 | Carmen Bozic | EVP and CMO | Sell | −2,329 | −$1.12M |
| 2026-03-03 | Reshma Kewalramani | CEO & President | Sell | −40,000 | −$19.74M |
| 2026-03-02 | Kristen Ambrose | SVP & Chief Accounting Officer | Sell | −357 | −$172.56K |
| 2026-02-26 | Kristen Ambrose | SVP & Chief Accounting Officer | MIXED | −769 | −$373.33K |
| 2026-02-26 | Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | MIXED | −2,295 | −$1.11M |
| 2026-02-26 | Jonathan Biller | EVP and Chief Legal Officer | MIXED | −2,089 | −$1.01M |
| 2026-02-26 | Carmen Bozic | EVP and CMO | F | −1,453 | −$704.86K |
| 2026-02-26 | Mark E. Bunnage | EVP, Chief Scientific Officer | MIXED | −1,202 | −$583.87K |
| 2026-02-26 | Reshma Kewalramani | CEO & President | F | −4,981 | −$2.42M |
| 2026-02-26 | Jeffrey M Leiden | Executive Chairman | F | −3,547 | −$1.72M |
| 2026-02-26 | Duncan McKechnie | EVP, Chief Commercial Officer | MIXED | −5,783 | −$2.82M |
| 2026-02-26 | Amit Sachdev | EVP Chief Patient & Ext Af Off | MIXED | −3,364 | −$1.63M |
| 2026-02-26 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | MIXED | −1,887 | −$915.72K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Reshma Kewalramani | CEO & President | 127,596 | $65.08M |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 73,149 | $37.31M |
| Stuart A Arbuckle | EVP, COO | 63,508 | $32.39M |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 53,572 | $27.33M |
| Charles F Wagner Jr | EVP, CO & FO | 47,042 | $24.00M |
| Bruce I Sachs | Director | 39,000 | $19.89M |
| Jeffrey M Leiden | Executive Chairman | 35,237 | $17.97M |
| David Altshuler | EVP, Chief Scientific Officer | 31,149 | $15.89M |
| Joy Liu | EVP and Chief Legal Officer | 19,131 | $9.76M |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | 19,100 | $9.74M |
| Carmen Bozic | EVP and CMO | 15,933 | $8.13M |
| Jonathan Biller | EVP and Chief Legal Officer | 14,604 | $7.45M |
| Kristen Ambrose | SVP & Chief Accounting Officer | 11,624 | $5.93M |
| Duncan McKechnie | EVP, Chief Commercial Officer | 11,001 | $5.61M |
| Jasper van Grunsven | EVP, CP and NPPO | 8,682 | $4.43M |
| Alan M Garber | Director | 7,344 | $3.75M |
| Mark E. Bunnage | EVP, Chief Scientific Officer | 7,284 | $3.72M |
| Lloyd Carney | Director | 6,315 | $3.22M |
| Sangeeta N. Bhatia | Director | 4,924 | $2.51M |
| Diana McKenzie | Director | 3,381 | $1.72M |
| Jennifer Schneider | Director | 2,190 | $1.12M |
| Nancy Thornberry | Director | 2,109 | $1.08M |
| Suketu Upadhyay | Director | 1,558 | $794.70K |
| Michel Lagarde | Director | 1,132 | $577.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.